Semaglutide and cardiovascular risk in type 1 diabetes: a predictive modelling analysis in a double-blind, randomised, placebo-controlled cross-over trial

Author(s):: Kugathasan, L.; Tsoukas, M.A.; Nardone, M.; Sridhar, V.S.; Muskiet, M.H.A. (0000-0003-4116-555X); Cherney, D.Z.I.; Haidar, A.; Pasqua, M.

Published: 2026
Publication type: Article / Letter to editor

cardiovascular diseaserisk predictionsemaglutidetype 1 diabetes

Date issued: 2026-02-02
Language: English
Publisher: WILEY
Is part of: Diabetes, Obesity and Metabolism: A Journal of Pharmacology and Therapeutics
hdl: 1887/4299044
doi: 10.1111/dom.70525